A phase 1 study of E2022 tape formulation for application sites and intervals
- Conditions
- Healthy elderly males
- Registration Number
- JPRN-jRCT2080222090
- Lead Sponsor
- Eisai Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- Male
- Target Recruitment
- 48
1. Male non-smokers (not smoking at least 4 weeks before Period 1) aged 65 years or older at informed consent,
2. BMI at screening is 18.5 kg/m2 or above - below 28.0 kg/m2,
3. Written informed consent,
4. Given full explanation of this study and is willing to and able to comply with the protocol requirements
1. Have a current or past history of disorder reequiring medical treatment within 8 weeks before the first application or infection within 4 weeks before the first application,
2. Have a disorder within 4 weeks before the first application which affects the evaluation of study drug such as psychiatric, gastrointestinal, hepatic, renal, respiratory, endocrinological, hematological, neurological or cardiovascular system, or congenital metabolic abnormality,
3. Have a history of gastrointestinal surgery (e.g., liver, kidney, digestive tract) which affects the pharmacokinetics of study drug,
4. Have a history of treatment-requiring drug or food allergy or seasonal allergy at screening,
5. Had caffeine-containing food or drink or alcohol within 72 hours before study drug application in Period 1,
6. Had nutritional suppliments, herbal preparations (including oriental medicines) or others (e.g., grapefruit-containing food or beverage which may affect drug metabolizing enzymes and transporters, within 1 weeks before Period 1,
7. Have used liquid products (including cosmetics) on study application sites (back, upper limbs, chest), patch, tape or bandage, within 4 weeks before Period 1,
8. Present or past clinical signs of skin hypersensitivity to topical product or atopic dermatitis,
9. Excessively hairy or have shaved at application sites (back, upper limbs, chest) within 4 weeks before Period 1,
10.Eczema, dermatitis, abnormal pigmentation, injury, or scar at application sites which may affect the evaluation of skin symptoms
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety<br>Evaluate the safety of E2022 tape formulation up to 168 hours after the end of application
- Secondary Outcome Measures
Name Time Method